Thanks, I do recall your post. However, Acrux have not announced anything on this matter. In their FY20 presentation, they still have Jublia one step away from approval/launch (slide 11).
Regarding the way Jublia is applied to the toe, after my post, I looked it up and indeed its applied directly on the toenail. If the other competitor products do the same thing, then I think it won't make a significant contribution to revenues when launched.
Add to My Watchlist
What is My Watchlist?
